“According to a new report published by Introspective Market Research, mRNA Vaccines and RNAi Therapeutics Market by Type, Application, and End User, The Global mRNA Vaccines and RNAi Therapeutics Market Size Was Valued at USD 1.2 Billion in 2023 and is Projected to Reach USD 15.1 Billion by 2032, Growing at a CAGR of 32.1% from 2024–2032.”

The mRNA vaccines and RNAi therapeutics market represents a transformative segment of the global biopharmaceutical industry, leveraging gene-based technologies to prevent and treat a wide range of diseases. mRNA vaccines work by instructing cells to produce antigens that trigger immune responses, while RNA interference (RNAi) therapeutics silence disease-causing genes at the molecular level. These approaches offer high specificity, rapid development timelines, and scalable manufacturing advantages over traditional therapies.

The market has gained substantial traction due to successful clinical and commercial outcomes in infectious diseases, oncology, and rare genetic disorders. The adaptability of mRNA platforms and the precision of RNAi-based treatments are reshaping drug discovery and development pipelines across the pharmaceutical landscape.

With increasing investments in genomics research, expanding clinical trials, and supportive regulatory frameworks, the mRNA vaccines and RNAi therapeutics market is poised for rapid growth globally, driven by both public health demand and innovation-led biopharma strategies.

Market Segmentation

The mRNA Vaccines and RNAi Therapeutics Market is segmented into Type, Application, and End User.
By Type, the market is categorized into mRNA Vaccines and RNAi Therapeutics.
By Application, the market is categorized into Infectious Diseases, Oncology, Rare Genetic Disorders, and Other Therapeutic Areas.
By End User, the market is categorized into Hospitals & Clinics, Research & Academic Institutes, and Pharmaceutical & Biotechnology Companies.

Growth Driver

One of the primary growth drivers of the mRNA vaccines and RNAi therapeutics market is the rising prevalence of infectious and chronic diseases worldwide. The success of mRNA-based COVID-19 vaccines validated the platform’s effectiveness, safety, and rapid scalability, encouraging further adoption across other therapeutic areas. Additionally, RNAi therapeutics are gaining acceptance due to their ability to precisely target genetic abnormalities, offering novel treatment options for previously untreatable conditions. Increasing R&D funding and strategic collaborations further accelerate market expansion.

Market Opportunity

A significant market opportunity lies in the expanding application of mRNA and RNAi technologies beyond infectious diseases into oncology, personalized medicine, and rare diseases. Advances in delivery systems, such as lipid nanoparticles, are improving stability and efficacy, unlocking broader clinical potential. Emerging markets with growing healthcare infrastructure and government-backed biotechnology initiatives also present lucrative growth avenues. Moreover, ongoing innovation in gene-silencing and mRNA platform customization is expected to create long-term commercial opportunities.

Detailed Segmentation

Title: mRNA Vaccines and RNAi Therapeutics Market, Segmentation

Line below:
The mRNA Vaccines and RNAi Therapeutics Market is segmented on the basis of Type, Application, and End User.

Type

The Type segment is further classified into mRNA Vaccines and RNAi Therapeutics. Among these, the mRNA Vaccines sub-segment accounted for the highest market share in 2023. This dominance is attributed to widespread vaccine deployment, strong clinical efficacy, and rapid manufacturing scalability. mRNA vaccines continue to attract significant investments for pipeline expansion across infectious diseases and oncology, reinforcing their leading position in the market.

Application

The Application segment is further classified into Infectious Diseases, Oncology, and Rare Genetic Disorders. Among these, the Infectious Diseases sub-segment accounted for the highest market share in 2023. The proven success of mRNA vaccines in global immunization programs and increasing preparedness for future pandemics have fueled demand in this segment. Continuous innovation and expanded indications are expected to sustain growth.

Some of The Leading / Active Market Players Are

·         Moderna, Inc. (USA)

·         BioNTech SE (Germany)

·         Pfizer Inc. (USA)

·         Alnylam Pharmaceuticals, Inc. (USA)

·         CureVac N.V. (Germany)

·         Arbutus Biopharma Corporation (Canada)

·         Ionis Pharmaceuticals, Inc. (USA)

·         Sanofi S.A. (France)

·         GlaxoSmithKline plc (UK)

·         AstraZeneca plc (UK)

·         Arrowhead Pharmaceuticals, Inc. (USA)

·         Translate Bio (USA)

·         Silence Therapeutics (UK)

·         Daiichi Sankyo Company, Limited (Japan)

·         and other active players.

Key Industry Developments

In March 2024, a leading biotechnology company announced positive Phase III trial results for an mRNA-based vaccine targeting multiple infectious strains.
The development highlighted improved immune response durability and reinforced confidence in next-generation mRNA platforms, accelerating commercialization timelines and partnership opportunities.

In October 2024, a major pharmaceutical firm expanded its RNAi therapeutics pipeline through a strategic acquisition.
This move strengthened its gene-silencing capabilities, broadened its rare disease portfolio, and signaled growing industry consolidation around RNA-based technologies.

Key Findings of the Study

·         mRNA vaccines dominate the market by type due to proven large-scale deployment

·         Infectious diseases lead application segments globally

·         North America remains the leading regional market

·         Rising R&D investments and platform innovation are key growth drivers

·         Strong CAGR reflects expanding therapeutic adoption

More Info:- https://introspectivemarketresearch.com/reports/mrna-vaccines-and-rnai-therapeutics-market/

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the mRNA Vaccines and RNAi Therapeutics Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global mRNA Vaccines and RNAi Therapeutics industry.

📞 Contact Us
Introspective Market Research Pvt. Ltd.
Phone: +91-91753-37569
Email: sales@introspectivemarketresearch.com
Web: www.introspectivemarketresearch.com